ALSO NOTED: FDA staffers back Ketek; Abbott gains a majority of Kos shares; and much more...
Free newsletter via e-mail
> In advance of an FDA advisory committee meeting on the controversial antibiotic Ketek, agency staffers have concluded that the data on the Sanofi-Aventis therapy demonstrates that it is safe and effective. Report
> Abbott's cash tender offer has won a majority of Kos Pharmaceuticals' shares. Report
> Amgen plans to repurchase up to $5 billion of its stock. Release
> Biomira has arranged $13 million in financing. Release
> Athenagen has begun a Phase II clinical study of the company's lead compound, GTS-21, in patients with Alzheimer's disease. Release
> OncoMethylome Sciences has licensed its prostate cancer test to a subsidiary of Johnson & Johnson. Report
> Eden Bioscience has received a delisting notification from Nasdaq. Report
And Finally… A new study says that a sleep apnea therapy also improves memory. Release
SHARE
WITH: